Abstract
The aim was to evaluate the impact of biofield treatment modality on mycobacterial strains in relation to antimycobacterials susceptibility. Mycobacterial sensitivity was analysed using 12 B BACTEC vials on the BACTEC 460 TB machine in 39 lab isolates (sputum samples) from stored stock cultures. Two American Type Culture Collection (ATCC) strains were also used to assess the minimum inhibitory concentration (MIC) of antimicrobials (Mycobacterium smegmatis 14468 and Mycobacterium tuberculosis 25177). Rifampicin, ethambutol and streptomycin in treated samples showed increased susceptibility as 3.33%, 3.33% and 400.6%, respectively, as compared to control in extensive drug resistance (XDR) strains. Pyrazinamide showed 300% susceptibility as compared to control in multidrug resistance (MDR) strains. Isoniazide did not show any improvement of susceptibility pattern against treated either in XDR or MDR strains of Mycobacterium as compared to control. Besides susceptibility, the resistance pattern of treated group was reduced in case of isoniazide (26.7%), rifampicin (27.6%), pyrazinamide (31.4%), ethambutol (33.43%) and streptomycin (41.3%) as compared to the untreated group of XDR strains. The MIC values of few antimicrobials were also altered in the treated group of Mycobacterium smegmatis. There was a significant reduction observed in MIC values of linezolid (8.0 to 2.0 μg/ml) and tobramycin (2.0 to 1.0 μg/ml); however, very slight changes occurred in the remaining antimicrobials of treated samples. There was no change of MIC values in the strain of Mycobacterium tuberculosis after biofield treatment. Biofield treatment effect on Mycobacterium against anti-tubercular drugs might be due to altered ligand-receptor/protein interactions at either enzymatic and/or genetic level with respect to anti-mycobacterium susceptibility and MIC values of antimicrobials.
Highlights
Global tuberculosis control is facing major challenges days
The aim of this study was to determine the impact of biofield treatment on XRD and multidrug resistance (MDR) strains of Mycobacterium against susceptibility patterns of antitubercular drugs
Antimycobacterial susceptibility and minimum inhibitory concentration (MIC) of antimicrobials The aim of this study was to determine the impact of biofield treatment on susceptibility patterns of anti-tubercular drugs to XRD and MDR strains of Mycobacterium
Summary
Global tuberculosis control is facing major challenges days. Multidrug resistance of Mycobacterium tuberculosis (MDR-TB) has recently become a serious public health burden. Drug resistant TB (XDR-TB; MDR resistance plus resistance to a fluoroquinolones and an aminoglycoside and to at least one of the three injectable drugs kanamycin, capreomycin and amikacin) is a form of tuberculosis which is a serious threat to human life. Drug resistance in M. tuberculosis are attributed to random mutations in the mycobacterial genome. All wild type population of M. tuberculosis contain a few mutant strains that are resistant to one of the drugs. These drug resistant strains emerge and become a dominant clone of the population when chemotherapy is intermittent or otherwise inadequate. Tuberculosis has become a threat in the modern era of antimicrobial warfare, because its unique characteristics give it enormous potential for developing resistance to even the strongest antimicrobials [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
